- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: November 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in November 2027, from ClinicalTrials.gov.
Trial readouts
79 trials: 31 phase 3 (including phase 2/3) and 48 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Nov 2027 | 4D Molecular Therapeutics, Inc. | 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 | Recruiting | NCT07064759 |
| Nov 2027 | AbbVie | UbrogepantStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | Migraine | Phase 3 | Active not recruiting | NCT06417775 |
| Nov 2027 | Bausch Health | LarsucosterolStudy to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Hepatitis | Phase 3 | Recruiting | NCT07428538 |
| Nov 2027 | Beijing Keymed Biosciences Co., Ltd. | CM512A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3) | Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) | Phase 3 | Not yet recruiting | NCT07807826 |
| Nov 2027 | Corvus Pharmaceuticals, Inc. | Soquelitinib, Belinostat, PralatrexateSoquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Hel… | Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma and 5 more | Phase 3 | Recruiting | NCT06561048 |
| Nov 2027 | Daewoong Pharmaceutical Co. LTD. | DWP16001, DWC202518To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC20251… | T2DM (Type 2 Diabetes Mellitus) | Phase 3 | Not yet recruiting | NCT07619833 |
| Nov 2027 | Elgan Pharma Ltd. | ELGN-2112Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants | Intestinal Malabsorption | Phase 3 | Recruiting | NCT05670951 |
| Nov 2027 | Eli Lilly and Company | LY3537982, Pembrolizumab, Cisplatin and 2 moreA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-s… | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | Phase 3 | Recruiting | NCT06119581 |
| Nov 2027 | Eli Lilly and Company | DonanemabA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Alzheimer Disease | Phase 3 | Active not recruiting | NCT05026866 |
| Nov 2027 | Jiangsu Hengrui Medicine | SHR-1819 InjectionA Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis | Adolescents With Moderate-to-severe Atopic Dermatitis | Phase 3 | Recruiting | NCT07309055 |
| Nov 2027 | Hanmi Pharmaceutical | HM11260CA Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dap… | Type 2 Diabetes | Phase 3 | Recruiting | NCT07379333 |
| Nov 2027 | Huons Co., Ltd. | HUC3-637, HUC3-637-REfficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension | Primary Open Angle Glaucoma (POAG), Ocular Hypertension | Phase 3 | Recruiting | NCT07335211 |
| Nov 2027 | Idorsia Pharmaceuticals Ltd. | DaridorexantA Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the… | Insomia Disorder | Phase 3 | Not yet recruiting | NCT07843329 |
| Nov 2027 | Kissei Pharmaceutical | KLH-2109, Leuprorelin acetateA Clinical Study of KLH-2109 in Patients With Endometriosis | Endometriosis | Phase 3 | Active not recruiting | NCT07015268 |
| Nov 2027 | Laboratoires Thea | sepofarsenStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | Leber Congenital Amaurosis 10, Blindness and 8 more | Phase 3 | Recruiting | NCT06891443 |
| Nov 2027 | Loxo Oncology, Inc. | Pirtobrutinib, Ibrutinib, Acalabrutinib and 1 moreStudy of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | Lymphoma, Mantle-Cell | Phase 3 | Active not recruiting | NCT04662255 |
| Nov 2027 | Neurocrine Biosciences | NBI-1117568NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Schizophrenia | Phase 3 | Recruiting | NCT07105098 |
| Nov 2027 | Neuvosyn Laboratories, LLC | Desiccated Porcine Thyroid Extract TabletsAn Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets. | Hypothyroidism | Phase 3 | Recruiting | NCT07747103 |
| Nov 2027 | NewAmsterdam Pharma Co N.V. | obicetrapib 10 mg + ezetimibe 10 mg FDC dailyA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | Lipidemia, Coronary Artery Disease and 1 more | Phase 3 | Active not recruiting | NCT06305559 |
| Nov 2027 | Sinocelltech Ltd. | SCTB35 injection, Rituxumab, Gemcitabine and 1 moreA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractor… | DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | NCT07570823 |
| Nov 2027 | UNITED THERAPEUTICS Corp | Inhaled Treprostinil, Treprostinil Ultrasonic NebulizerStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Recruiting | NCT05943535 |
| Nov 2027 | Vanda Pharmaceuticals Inc. | iloperidoneRandomized Withdrawal Study in Patients With Schizophrenia | Schizophrenia | Phase 3 | Recruiting | NCT06961968 |
| Nov 2027 | Vanda Pharmaceuticals Inc. | Tasimelteon Oral SuspensionEvaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | Insomnia Disorder | Phase 3 | Recruiting | NCT06953869 |
| Nov 1, 2027 | AstraZeneca | Datopotamab deruxtecan, Durvalumab, Carboplatin and 4 morePhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Gen… | NSCLC | Phase 3 | Active not recruiting | NCT05687266 |
| Nov 1, 2027 | AstraZeneca | Capivasertib, Fulvestrant, Palbociclib and 2 moreCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Locally Advanced (Inoperable) or Metastatic Breast Cancer | Phase 3 | Active not recruiting | NCT04862663 |
| Nov 1, 2027 | Otsuka Pharmaceutical | JNT-517A Long-Term Study of JNT-517 in Participants With Phenylketonuria | Phenylketonuria (PKU) | Phase 3 | Recruiting | NCT06628128 |
| Nov 1, 2027 | Taiho Oncology, Inc. | Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine and 1 moreA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND St… | Myelodysplastic Syndromes, Acute Myeloid Leukemia and 2 more | Phase 2/3 | Recruiting | NCT04256317 |
| Nov 1, 2027 | YS Life Science Co., Ltd. | Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH) | Phase 3 | Recruiting | NCT07661329 |
| Nov 4, 2027 | AstraZeneca | TozorakimabEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | Viral Lung Infection and Acute Respiratory Failure | Phase 3 | Recruiting | NCT05624450 |
| Nov 5, 2027 | GSK | Risvutatug rezetecan (Ris-Rez), TopotecanA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] | Neoplasms, Lung | Phase 3 | Recruiting | NCT07099898 |
| Nov 5, 2027 | Sanofi | rilzabrutinibStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment | Immune Thrombocytopenia | Phase 3 | Recruiting | NCT07007962 |
| Nov 2027 | AbbVie | Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab and 3 moreStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhi… | Non Small Cell Lung Carcinoma, c-MET | Phase 1/2 | Recruiting | NCT06772623 |
| Nov 2027 | AbbVie | IcalcaprantA Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | Bipolar I Disorder, Bipolar II Disorder | Phase 2 | Recruiting | NCT06696755 |
| Nov 2027 | Akeso | AK139A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis | Moderate-to-Severe Atopic Dermatitis | Phase 2 | Not yet recruiting | NCT07502222 |
| Nov 2027 | Akeso | AK129, AK117A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Phase 1/2 | Recruiting | NCT06642792 |
| Nov 2027 | Alto Neuroscience, Inc. | ALTO-207ALTO-207 in Adults With Treatment-resistant Depression (TRD) | Treatment-resistant Depression (TRD) | Phase 2 | Recruiting | NCT07553637 |
| Nov 2027 | Angitia Incorporated Limited | AGA2115Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) | Osteogenesis Imperfecta (OI) | Phase 2 | Recruiting | NCT07062588 |
| Nov 2027 | BIONCaRT GmbH | BP CC 001Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint | Cartilage Damage | Phase 1/2 | Recruiting | NCT06981741 |
| Nov 2027 | Beijing Sungen Biomedical Technology Co., Ltd | SGC001 injectionStudy of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy | Acute Pancreatitis | Phase 2 | Recruiting | NCT07803965 |
| Nov 2027 | BioAge Labs, Inc. | Oral BGE-102, Anti-VEGF, ShamA Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema | Diabetic Macular Edema (DME) | Phase 2 | Recruiting | NCT07812090 |
| Nov 2027 | BioInvent International AB | BI1206A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Solid Tumor, Adult | Phase 1/2 | Recruiting | NCT04219254 |
| Nov 2027 | BioNTech | BNT3212, PumitamigA First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Adva… | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT07147348 |
| Nov 2027 | Calico Life Sciences LLC | FosigotifatorAn Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease | Vanishing White Matter Disease | Phase 1/2 | Recruiting | NCT05757141 |
| Nov 2027 | Cartesian Therapeutics | Descartes-08Descartes-08 in Autoantibody Myositis | Antisynthetase Syndrome | Phase 2 | Recruiting | NCT07391605 |
| Nov 2027 | Sino Biopharmaceutical Limited | TQ05105 tabletsA Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease | Chronic Graft Versus Host Disease | Phase 2 | Recruiting | NCT06300320 |
| Nov 2027 | Sino Biopharmaceutical Limited | TQH3906 capsuleA Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Phase 2 | Recruiting | NCT07509892 |
| Nov 2027 | Sino Biopharmaceutical Limited | Benmelstobart injection combined with Anlotinib hydrochlor…Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveo… | Alveolar Soft Part Sarcoma | Phase 2 | Recruiting | NCT07548177 |
| Nov 2027 | Curis Inc | Emavusertib, ZanubrutinibA Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Oth… | Chronic Lymphocytic Leukemia, B-cell Malignancies | Phase 2 | Recruiting | NCT07271667 |
| Nov 2027 | Eddingpharm (Zhuhai) Co., Ltd. | EDP167 100mg, EDP167 200mg, EDP167 300mgPhase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia | Mixed Dyslipidemia | Phase 2 | Not yet recruiting | NCT07799129 |
| Nov 2027 | Eli Lilly and Company | BrenipatideA Study of Brenipatide in Adult Participants With Schizophrenia | Schizophrenia | Phase 2 | Recruiting | NCT07410507 |
| Nov 2027 | Eli Lilly and Company | BrenipatideA Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) | Bipolar Disorder | Phase 2 | Recruiting | NCT07286175 |
| Nov 2027 | Faron Pharmaceuticals | bexmarilimab (1mg/kg), azacitidine, bexmarilimab (3mg/kg)Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes | Higher Risk Myelodysplastic Syndromes | Phase 2 | Recruiting | NCT07672769 |
| Nov 2027 | Genfleet Therapeutics (Shanghai) Inc. | GFH276, Cetuximab, Nab paclitaxel and 5 moreA Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harb… | Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma and 1 more | Phase 1/2 | Recruiting | NCT07678593 |
| Nov 2027 | Hemab ApS | SutacimigA Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency | Congenital Factor VII Deficiency | Phase 2 | Recruiting | NCT07347249 |
| Nov 2027 | InventisBio Co., Ltd | D-2570 Dose 1, D-2570 Dose 2, D-2570 Dose 3Study of D-2570 in Subjects With Non-Segmental Vitiligo | Vitiligo, Non-Segmental Vitiligo (NSV) | Phase 2 | Recruiting | NCT07625891 |
| Nov 2027 | Jiangsu Hengrui Medicine | SHR-4394, Rezvilutamide, HRS-5041 Tablets and 1 moreA Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | Prostate Cancer | Phase 1/2 | Recruiting | NCT07407283 |
| Nov 2027 | Jiangsu Hengrui Medicine | FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin, FH-006 ; SHR-1316 ; BP102, FH-006; SHR-1316 ; SHR-8068A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer | Lung Cancer | Phase 2 | Recruiting | NCT07241767 |
| Nov 2027 | Jiangsu Hengrui Medicine | RSS0343 TabellaStudy of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis | Adolescent Asthma | Phase 2 | Recruiting | NCT06775340 |
| Nov 2027 | Laboratoires Thea | T10430 lower dose, T10430 middle dose, T10430 higher doseSafety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression | Myopia | Phase 2 | Recruiting | NCT07522242 |
| Nov 2027 | MapLight Therapeutics, Inc. | ML-004 (IR)/(ER) tabletML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) | Autism Spectrum Disorder | Phase 2 | Active not recruiting | NCT05889273 |
| Nov 2027 | Marea Therapeutics | MAR001Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol | Hypertriglyceridemia | Phase 2 | Recruiting | NCT07028749 |
| Nov 2027 | NovelMed Therapeutics | NM8074Study of NM8074 in Patients with Dermatomyositis (DM) | Dermatomyositis | Phase 2 | Not yet recruiting | NCT06887738 |
| Nov 2027 | Orca Biosystems, Inc. | Orca-TTrial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Synd… | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and 1 more | Phase 2 | Recruiting | NCT07216443 |
| Nov 2027 | Qilu Pharmaceutical Co., Ltd. | QLS32015, Pomalidomide, Dexamethasone and 3 morePhase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | Relapsed or Refractory Multiple Myeloma | Phase 2 | Recruiting | NCT07018050 |
| Nov 2027 | Relmada Therapeutics, INC. | NDV01 intravesical controlled release formulation of gemci…A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC | Non Muscle Invasive Bladder Cancer | Phase 2 | Recruiting | NCT06663137 |
| Nov 2027 | SAB Biotherapeutics, Inc. | High Dose SAB-142, Low Dose SAB-142SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Type 1 Diabetes | Phase 2 | Recruiting | NCT07187531 |
| Nov 2027 | Serum Institute of India Pvt. Ltd. | 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 s…, RABIVAX-S and 3 morePfs230D1 + R21 in Matrix-M1 in African School Children and Adults | Prevention of Malaria Transmission and Clinical Malaria | Phase 2 | Active not recruiting | NCT07147400 |
| Nov 2027 | Shenyang Sunshine Pharmaceutical Co., LTD. | SSGJ-706, SPGL008, ChemotherapySPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer | Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | NCT07874984 |
| Nov 2027 | Vera Therapeutics, Inc. | AtaciceptAtacicept in Multiple Glomerular Diseases | pMN, IgAN and 3 more | Phase 2 | Recruiting | NCT06983028 |
| Nov 2027 | Argenx SE | Efgartigimod PH20 SC - prefilled syringeA Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Anti… | Antibody-mediated Rejection | Phase 2 | Active not recruiting | NCT06503731 |
| Nov 1, 2027 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM2017, FruquintinibA Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer | Colorectal Cancer Metastatic | Phase 1/2 | Not yet recruiting | NCT07621159 |
| Nov 1, 2027 | Innovent Biologics | Part B -Telitacicept, Part A - IBI355A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease | Sjögren's Disease | Phase 2 | Not yet recruiting | NCT07836660 |
| Nov 1, 2027 | Servier | S241656, PosaconazoleA Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia and 1 more | Phase 1/2 | Not yet recruiting | NCT07719348 |
| Nov 2, 2027 | Pfizer | PF-08634404, Ipilimumab, Axitinib and 1 moreSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Ad… | Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma and 11 more | Phase 1/2 | Recruiting | NCT07227415 |
| Nov 3, 2027 | Hemay Pharmaceutical PTY. LTD. | Hemay5394 group, Control groupTo Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis | Safety, Efficiency | Phase 2 | Not yet recruiting | NCT07877155 |
| Nov 4, 2027 | Merck & Co. | Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate and 6 moreA Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Malignant Neoplasm | Phase 2 | Recruiting | NCT06979596 |
| Nov 5, 2027 | AstraZeneca | AZD6793A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Recruiting | NCT07082738 |
| Nov 5, 2027 | GSK | Ris-Rez, G-CSFA Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) | Sarcoma | Phase 1/2 | Recruiting | NCT07602777 |
| Nov 5, 2027 | Haisco Pharmaceutical Group Co., Ltd. | HSK39297 200mgQD, HSK39297 300mgQDStudy to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN | Lupus Nephritis (LN) | Phase 2 | Recruiting | NCT07363460 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.


